These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12463603)

  • 1. The clinical implications of mixed lymphocyte reaction with leukemic cells.
    Kim HJ; Kim TG; Cho HI; Han H; Min WS; Kim CC
    Int J Hematol; 2002 Nov; 76(4):370-5. PubMed ID: 12463603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.
    Sondel PM; Hank JA; Wendel T; Flynn B; Bozdech MJ
    J Clin Invest; 1983 Jun; 71(6):1779-86. PubMed ID: 6223050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
    Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
    Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
    Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
    J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
    Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R
    Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.
    Norde WJ; Overes IM; Maas F; Fredrix H; Vos JC; Kester MG; van der Voort R; Jedema I; Falkenburg JH; Schattenberg AV; de Witte TM; Dolstra H
    Blood; 2009 Mar; 113(10):2312-23. PubMed ID: 19074734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
    Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
    Nagai K; Hashimoto H; Itoh K; Matsushita A; Shimoji S; Kimura T; Inoue D; Mori M; Nagai Y; Tabata S; Yanagida M; Takahashi T
    Rinsho Ketsueki; 2010 Jun; 51(6):413-21. PubMed ID: 20622488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.
    Woiciechowsky A; Regn S; Kolb HJ; Roskrow M
    Leukemia; 2001 Feb; 15(2):246-55. PubMed ID: 11236940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
    Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.
    Falkenburg JH; Goselink HM; van der Harst D; van Luxemburg-Heijs SA; Kooy-Winkelaar YM; Faber LM; de Kroon J; Brand A; Fibbe WE; Willemze R
    J Exp Med; 1991 Jul; 174(1):27-33. PubMed ID: 2056279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation.
    Yazaki M; Takahashi T; Ito Y; Ito T; Mori C; Wada Y
    Bone Marrow Transplant; 2000 Aug; 26(4):451-3. PubMed ID: 10982294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.
    Weber G; Gerdemann U; Caruana I; Savoldo B; Hensel NF; Rabin KR; Shpall EJ; Melenhorst JJ; Leen AM; Barrett AJ; Bollard CM
    Leukemia; 2013 Jul; 27(7):1538-47. PubMed ID: 23528871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation.
    Epperson DE; Margolis DA; McOlash L; Janczak T; Barrett AJ
    Br J Haematol; 2001 Jul; 114(1):57-62. PubMed ID: 11472345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.